𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL

✍ Scribed by Alison J. Birtle; Alex Freeman; John R.W. Masters; Heather A. Payne; Stephen J. Harland; contributors to the BAUS Section of Oncology Cancer Registry

Book ID
109051895
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
497 KB
Volume
96
Category
Article
ISSN
1464-4096

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clinical features of patients who presen
Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL : The β€œPSA negative” patients
✍ Alison J. Birtle; Alex Freeman; John R. W. Masters; Heather A. Payne; Stephen J. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 108 KB πŸ‘ 1 views

## Background: Although < 1% of men present with prostate-specific antigen (psa)-negative prostate carcinoma, in that they have serum psa levels much lower than the tumor burden would suggest, such patients represent a management dilemma. to the authors' knowledge, little information exists in the

Predictive modeling for the presence of
Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≀ 10 ng/mL
✍ Mark Garzotto; R. Guy Hudson; Laura Peters; Yi-Ching Hsieh; Eduardo Barrera; Mot πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 95 KB

## Abstract ## BACKGROUND The objective of the current study was to develop a model for predicting the presence of prostate carcinoma using clinical, laboratory, and transrectal ultrasound (TRUS) data. ## METHODS Data were collected on 1237 referred men with serum prostate specific antigen (PSA)